Bonesupport, an orthopedic device manufacturer based in Sweden, announced that it received CE Mark clearance from the European Union for its Cerament|G antibiotic bone substitute.
According to a press release by the company, the Cerament|G bone substitute is a ceramic substance with osteoconductive properties that can reduce the risk of bone infection and osteomyelitis while promoting bone healing. The Cerament|G bone graft substitute is used by surgeons to create a framework for healthy bone regrowth within six to 12 months after implantation. Since bone grafts carry a moderate risk of infection, the Cerament|G substance is designed to prevent colonization by microorganisms.
Dr. Lars Lidgren is an orthopedic surgery professor at Lund University Hospital. Dr. Lidgren helped research the company’s antibiotic bone graft substitute. In prepared remarks, she said, "Cerament|G is an important advancement in the management of osteomyelitis with great potential to enhance outcomes for patients, and improve the health economics of infection management by reducing the systemic antibiotic burden, with less surgical interventions per patient, and less risk of developing antibiotic resistance."
According to information from the company, the worldwide osteomyelitis market has an estimated value of $1.7 billion. Bone regrowth and treatment can take years and comprises processes like debridement and management of the hollow space inside grafted bones.
Osteomyelitis is estimated to affect at least 150 million people every year. For these patients, years of antibiotic therapy are needed to prevent deep bone infections. Unmanaged deep bone infections may require surgical interventions or amputation. Since the Cerament|G elutes antibiotics, patients have a safer treatment option for osteomyelitis.